ESMO 2025: Ribociclib + NSAI Reduced the Risk of Invasive and Distant Recurrence of HR+/HER2−Early Breast Cancer

At ESMO 2025, John Crown, MD, Consultant Medical Oncologist at St Vincent’s Hospital Dublin and Professor at University College Dublin, presented the 5-year analysis of the NATALEE trial. The study showed a sustained and improved invasive disease-free survival with ribociclib plus aromatase inhibitor in hormone receptor-positive, HER2-negative early breast cancer, including significant benefit for node-negative patients. Extended follow-up will provide further insights into overall survival.